🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re excited to announce that we’re partnering with Abbott and FreeStyle Libre to integrate the FreeStyle Libre 3 Plus sensor with the iLet Bionic Pancreas. Learn more: betabionics.com/beta-bionics-a…

GLP-1 receptor agonists associated with a significantly lower incidence of glaucoma, ocular hypertension, a Compared to metformin in people with type 2 diabetes. sciencedirect.com/science/articl…

GLP-1 RA, in addition to SGLT2i, associated with a significantly lower risk of heart failure hospitalisation sciencedirect.com/science/articl…

📉#Tirzepatide reduces the progression of #prediabetes to #Type2Diabetes by 94% compared to placebo 👀, according to SURMOUNT-1 trial results 👏 Treatment of the underlying obesity improves overall health and prevents obesity-related complications. These data add to an ever

Read our DIABETES & TECHNOLOGY special issue: inc 9 reviews on diabetes tech use in T1D, T2D, older adults, children, pregnancy, CFRD, CKD, hospital settings & exercise. Also including the views of people living with diabetes and an editorial by Kar & co diabetologia-journal.org/collections/di…

Important points made in the Obesity Medicine Association’s latest position statement on compounded GLP1s 💉: “Compounded drugs pose a higher risk to patients than FDA-approved drugs because compounded drugs do not undergo FDA premarket review for safety, effectiveness, or

In this month's issue of @CJASN - Optimizing the timing an sequencing of kidney protective therapies in CKD journals.lww.com/cjasn/fulltext… #kidneyGDMT #4pillarsCKD

Join the Obesity Care and Weight Management Patient Engagement Training by the American Diabetes Association® on Wednesday, October 16 at 4:00 p.m. ET to learn how to address weight stigma in health care. Register now at bit.ly/3zdEqD0.

GLP-1 based therapies led to ~30% total body lean mass loss, in a newly published meta-analysis. This proportion is on the higher end of what might be expected with lifestyle-based weight loss. The 30% figure aligns more closely with what is seen with bariatric surgery. What

Over 1 billion people live with #obesity. There is an urgent need for a universal definition & diagnosis. 🆕 A The Lancet Diabetes & Endocrinology Commission introduces a new model with categories: clinical obesity (an illness) & pre-clinical obesity. This reframing identifies medically meaningful

The Lancet Commission on Clinical Obesity has made it official: The clinical disease of obesity is all about health. Not size, not appearance, not BMI. HT: Francesco Rubino Dr Robert Kushner The Lancet Diabetes & Endocrinology conscienhealth.org/2025/01/lancet…

STEP UP Trial Top-line Results for Semaglutide 7.2 mg Novo Nordisk has shared results from the STEP UP trial evaluating semaglutide 7.2 mg for obesity treatment: 🔹Average weight loss of 20.7% with treatment adherence over 72 weeks. 🔹18.7% weight loss on average, regardless of

This is a great article and we need to highlight this more to protect patients from potentially harmful treatment of a disease that doesn’t have comprehensive universal coverage.

Definition and diagnostic criteria of #clinical #obesity thelancet.com/journals/landi… #FREE to read with registration (also FREE)

Overview of thyroid hormone action in the liver. Thyroid hormone regulates: ✔️Gluconeogenesis ✔️De novo lipogenesis ✔️Fatty acid oxidation ✔️Cholesterol metabolism ✔️Lipophagy journals.lww.com/hepcomm/fullte…

Nutritional Strategies for Reducing Postprandial Glycemia 1️⃣ Premeal nutrient intake modulates postprandial glycemia by delaying gastric emptying and influencing incretin hormone secretion, which is crucial for individuals with type 2 diabetes. 2️⃣ Protein is the most potent

As the potency of #ObesityMedicines for #WeightLoss grows, FDA and HCPs need to refocus on the right target for #ObesityCare. It's all about health gain, not just weight loss. conscienhealth.org/2025/02/weight…

Two years of empagliflozin slowed kidney disease progression and reduced cardiovascular risk. In the follow-up study to the EMPA-KIDNEY trial, empagliflozin had additional cardiorenal benefits after discontinuation. Full study results and Research Summary: nej.md/3NE3W7K

Join us at #ADASciSessions for United in Care: Momentum in Multi-Specialty Care Management. June 21, 12:30 P.M. CT, ADA Hub, Chicago, IL. Featuring Jeff Giullian & Dr. Samar Hafida,MD on advancing team-based care for chronic disease. Register: bit.ly/3DUDbGC DaVita Kidney Care

Join us at #ADASciSessions for United in Care: Momentum in Multi-Specialty Care Management. June 21, 12:30 P.M. CT, ADA Hub, Chicago, IL. Featuring Jeff Giullian & Dr. Samar Hafida,MD on advancing team-based care for chronic disease. Register: bit.ly/3DUDbGC DaVita Kidney Care